Fresenius Medical Care AG & Co. KGaA
FMS · New York Stock Exchange · USD
22,95USD
−0,45 (−1,92 %)Stand 9. Nov., 21:00
Kennzahlen
- Eröffnung
- 23,05
- Vortag
- 23,40
- Tagesspanne
- 22,89 – 23,07
- 52 Wochen
- 20,02 – 26,42
- Volumen
- 970.033
- Ø Volumen
- 892.512
- Börsenwert
- 12,21 Mrd. $
- KGV
- 13,7
- Gewinn je Aktie (TTM)
- 1,51
- Dividendenrendite
- 3,6 %
- Beta
- 0,8
- Nächste Zahlen
- 23. Feb. 2027
Finanzen
| EUR | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 19,63 Mrd. | 19,34 Mrd. | 19,45 Mrd. | 19,4 Mrd. | 17,62 Mrd. |
| Herstellungskosten | 14,6 Mrd. | 14,58 Mrd. | 14,53 Mrd. | 14,5 Mrd. | 12,85 Mrd. |
| Bruttogewinn | 5,03 Mrd. | 4,76 Mrd. | 4,93 Mrd. | 4,89 Mrd. | 4,77 Mrd. |
| Forschung und Entwicklung | 157,98 Mio. | 183,49 Mio. | 231,97 Mio. | 228,62 Mio. | 220,78 Mio. |
| Vertrieb und Verwaltung | 3,03 Mrd. | 3,14 Mrd. | 3,2 Mrd. | 3,17 Mrd. | 2,77 Mrd. |
| Operatives Ergebnis | 1,83 Mrd. | 1,47 Mrd. | 1,37 Mrd. | 1,51 Mrd. | 1,85 Mrd. |
| EBITDA | 3,4 Mrd. | 3,21 Mrd. | 3,21 Mrd. | 3,42 Mrd. | 3,55 Mrd. |
| Nettogewinn | 978,37 Mio. | 537,91 Mio. | 499 Mio. | 673,41 Mio. | 969,31 Mio. |
| Gewinn je Aktie (verwässert) | 1,68 | 0,92 | 0,85 | 0,57 | 0,83 |
Umsatz nach Segment
Produkte · FY 2025
- Health Care Services13,1 Mrd. €74,79 %−13,18 %
- Health Care Products4,41 Mrd. €25,21 %+3,84 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- United States14,18 Mrd. €96,63 %
- Germany494,57 Mio. €3,37 %+3,26 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 13,7
- Kurs-Umsatz-Verhältnis
- 0,6
- Kurs-Buchwert-Verhältnis
- 0,8
- PEG
- 0,6
- Bruttomarge
- 26,5 %
- Operative Marge
- 10,6 %
- Nettomarge
- 4,2 %
- Verschuldungsgrad
- 0,9
- EV/EBITDA
- 5,9
- Eigenkapitalrendite
- 6,3 %
- Kapitalrendite (ROIC)
- 6,1 %
- Free-Cashflow-Rendite
- 16,5 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 25,6 % | 24,6 % | 25,3 % | 25,2 % | 27,1 % |
| Operative Marge | 9,3 % | 7,6 % | 7,0 % | 7,8 % | 10,5 % |
| Nettomarge | 5,0 % | 2,8 % | 2,6 % | 3,5 % | 5,5 % |
| KGV | 12,1 | 23,9 | 22,2 | 26,5 | 34,4 |
| Kurs-Umsatz-Verhältnis | 0,6 | 0,7 | 0,6 | 0,9 | 1,9 |
| Kurs-Buchwert-Verhältnis | 0,8 | 0,9 | 0,8 | 1,3 | 2,6 |
| Verschuldungsgrad | 0,8 | 0,8 | 0,9 | 0,9 | 1,0 |
| Liquidität 3. Grades | 1,3 | 1,4 | 1,4 | 1,3 | 1,1 |
| Dividendenrendite | 3,4 % | 2,7 % | 3,0 % | 2,2 % | 1,2 % |
| Unternehmenswert | 21 Mrd. | 22,65 Mrd. | 21,73 Mrd. | 29,84 Mrd. | 45,29 Mrd. |
| EV/EBITDA | 6,2 | 7,1 | 6,8 | 8,7 | 12,8 |
| Eigenkapitalrendite | 6,8 % | 3,7 % | 3,7 % | 4,8 % | 7,6 % |
| Kapitalrendite (ROIC) | 5,3 % | 3,5 % | 3,3 % | 3,5 % | 4,8 % |
| Free-Cashflow-Rendite | 14,4 % | 13,1 % | 17,6 % | 8,1 % | 4,9 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +1,5 % | −0,6 % | +0,3 % | +10,1 % | −1,3 % |
| Bruttogewinn | +5,7 % | −3,4 % | +0,6 % | +2,5 % | −13,8 % |
| Operatives Ergebnis | +24,5 % | +7,2 % | −9,4 % | −18,4 % | −19,6 % |
| Nettogewinn | +81,9 % | +7,8 % | −25,9 % | −30,5 % | −16,8 % |
| Gewinn je Aktie | +83,6 % | +7,6 % | +47,8 % | −30,7 % | −36,6 % |
| Freier Cashflow | +0,5 % | −13,2 % | +34,7 % | −11,7 % | −48,6 % |
| Dividende je Aktie | +17,1 % | +6,3 % | +66,1 % | +0,7 % | −15,4 % |
Analysten
Einstufungen · Hold
- 0Stark kaufen
- 4Kaufen
- 14Halten
- 3Verkaufen
- 0Stark verkaufen
Kursziel
23,67
Durchschnitt · +3,14 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 19,67 Mrd. | 20,32 Mrd. | 21,05 Mrd. |
| Umsatz (Tief – Hoch) | 18,7 Mrd. – 20,02 Mrd. | 20,26 Mrd. – 20,36 Mrd. | 20,02 Mrd. – 21,43 Mrd. |
| Gewinn je Aktie (Ø) | 2,05 | 2,04 | 2,38 |
| Gewinn je Aktie (Tief – Hoch) | 1,99 – 2,16 | 1,82 – 2,21 | 2,23 – 2,44 |
| Analysten | 4 | 4 | 2 |
Letzte Änderungen
- Barclays9. Nov. 2026Equal Weight → Underweight
- Truist Securities12. Okt. 2026Hold
- Bernstein6. Aug. 2026Market Perform
- Goldman Sachs20. Jan. 2026Buy → Neutral
- B of A Securities15. Okt. 2025Neutral → Underperform
- UBS2. Sept. 2025Neutral → Sell
- Truist Securities12. Mai 2025Hold
- Truist Securities6. Jan. 2025Hold
Quartalszahlen
Nächste Zahlen: 23. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,65 | 0,62 | 0,59 | 0,65 | 0,59 | 0,50 | 0,43 | 0,41 |
| Gewinn je Aktie · Tatsächlich | 0,64 | 0,66 | 0,53 | 0,83 | 0,64 | 0,52 | 0,44 | 0,48 |
| Abweichung | −1,69 % | +7,14 % | −10,17 % | +28,28 % | +8,47 % | +4,00 % | +2,33 % | +17,07 % |
| Umsatz · Tatsächlich | 5,53 Mrd. | 5,6 Mrd. | 5,4 Mrd. | 5,97 Mrd. | 5,72 Mrd. | 5,64 Mrd. | 5,35 Mrd. | 5,27 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 22. Mai 2026 | 8. Juni 2026 | 0,86 |
| 23. Mai 2025 | 6. Juni 2025 | 0,81 |
| 17. Mai 2024 | 3. Juni 2024 | 0,63 |
| 17. Mai 2023 | 1. Juni 2023 | 0,62 |
| 13. Mai 2022 | 27. Mai 2022 | 0,71 |
| 24. Mai 2021 | 7. Juni 2021 | 0,83 |
| 28. Aug. 2020 | 11. Sept. 2020 | 0,71 |
| 17. Mai 2019 | 31. Mai 2019 | 0,66 |
| 21. Mai 2018 | 4. Juni 2018 | 0,63 |
| 11. Mai 2017 | 26. Mai 2017 | 0,51 |
| 10. Mai 2016 | 23. Mai 2016 | 0,44 |
| 15. Mai 2015 | 1. Juni 2015 | 0,44 |
Aktiensplits
- 4. Dez. 20122:1
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 7,73 %
- Investoren mit 13F-Meldung
- 243
Größte Investoren
- PZENA INVESTMENT MANAGEMENT LLC2,78 %14,99 Mio.
- MORGAN STANLEY0,81 %4,35 Mio.
- DODGE & COX0,71 %3,83 Mio.
- FIDUCIARY MANAGEMENT INC /WI/0,54 %2,94 Mio.
- BRANDES INVESTMENT PARTNERS, LP0,36 %1,92 Mio.
- MILLENNIUM MANAGEMENT LLC0,29 %1,57 Mio.
- TODD ASSET MANAGEMENT LLC0,24 %1,31 Mio.
- GOLDMAN SACHS GROUP INC0,17 %898.668
Insider-Geschäfte
- Renkewitsch Olga18. März 2026 · officerVerkauf0 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Führung
- Helen GizaChair of Management Board & Chief Executive Officer
- Cassie McLeanChief Executive Officer of Care Delivery & Member of Management Board
- Joseph E. Turk Jr.Chief Executive Officer of Care Enablement & Member of Management Board
- Charles Hugh-JonesGlobal Chief Medical Officer & Member of Management Board
- Martin FischerChief Financial Officer & Member of the Management Board
- Jorg HaringMember of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director
- CEO
- Shervin J. Korangy
- Mitarbeitende
- 108.165
- Hauptsitz
- Bad Homburg, HE, DE
- Sektor
- Healthcare
- Branche
- Medical - Care Facilities
- Börsengang
- 17. Sept. 1996
- Website
- freseniusmedicalcare.com
Nachrichten
- MarketBeat · 4. Nov., 1:15What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call
- Seeking Alpha · 3. Nov., 12:46Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript
- PRNewsWire · 3. Nov., 7:00Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook
- Reuters · 3. Nov., 1:40Fresenius Medical cuts top end of 2026 profit outlook
- Zacks Investment Research · 23. Okt., 11:56FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI
- PRNewsWire · 21. Okt., 18:10Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
- Business Wire · 21. Okt., 12:22Fly Alliance to Replace Entire Flight Management System with flyExclusive's AI-Powered Contrails FMS
- PRNewsWire · 19. Okt., 9:00Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
- Zacks Investment Research · 7. Okt., 15:40Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
- Zacks Investment Research · 29. Sept., 10:46Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.